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SummaryTriglycerides are retained in the human gut long after ingestion of dietary fat. Oral glucose subsequently mobilizes triglyceride stores from the gut by recruiting cytoplasmic lipid droplets for chylomicron synthesis and secretion.

Hypertriglyceridemia, resulting from accumulation of circulating triglyceride (TG)-rich lipoprotein (TRL) particles in both fasting and postprandial states, is a highly prevalent condition and a significant risk factor for cardiovascular disease.[@bib1] TGs, the main form of dietary fat, are hydrolyzed into fatty acids (FAs), glycerol, and monoglycerides by digestive enzymes in the intestinal lumen. These digestive products of dietary TGs are taken up by absorptive cells of the small intestine (enterocytes), where the majority of re-esterified TG is packaged into chylomicrons (CMs) and secreted into the circulation via the lymphatic system.[@bib2] There is increasing evidence that, beyond the dominant regulation by lipid substrate availability, the intestine actively participates in the regulation of whole-body lipid metabolism via nutrient, hormonal, metabolic, and neural regulatory pathways.[@bib3]

Aside from rapid TG incorporation into CMs, the intestine can store a considerable quantity of fat for several hours after the absorptive phase.[@bib4] Studies in human beings suggest that dietary lipids originating from an earlier high-fat meal may contribute to CM TG after prolonged storage in the gut.[@bib5], [@bib6], [@bib7], [@bib8] In addition, abundant lipid droplets are detected in human enterocytes 6 hours after ingestion of a high-fat liquid meal,[@bib9] and in mice up to 12 hours after an oral fat gavage.[@bib10] The exact site(s) of retained intestinal lipid stores and the quantity stored in each location have not been well characterized. Lipid droplets have been visualized in the cytoplasm of jejunal enterocytes in human beings[@bib9] and mice,[@bib10] and CMs have been observed in intracellular secretory pathways, in the lamina propria, and lacteals of the mesenteric lymphatics in human beings[@bib9] and rodents.[@bib10], [@bib11], [@bib12] Cytoplasmic lipid droplets (CLDs) are the best studied of these various lipid pools with respect to lipid storage and mobilization. CLDs consist of a neutral lipid core surrounded by a phospholipid monolayer. Numerous CLD-associated proteins have been identified and several have been shown to regulate CLD storage and metabolism.[@bib13], [@bib14] The exact role of CLDs in the process of dietary fat absorption and their contribution to CM assembly and secretion is unknown, but studies in mice have indicated that CLD stores undergo dynamic changes in response to a dietary fat challenge.[@bib15] Therefore, it is thought that CLDs may function as a temporary storage pool of neutral lipids for incorporation in CMs at later time points.[@bib16], [@bib17]

Various dietary and hormonal factors play a role in mobilizing TGs stored within enterocytes from a previous meal. Several stimuli, including mixed meals,[@bib18] glucose ingestion,[@bib9] the gut hormone glucagon-like peptide-2 (GLP-2),[@bib19] and sham fat feeding,[@bib8] may trigger the mobilization of intestinal lipid stores. Ingestion of a mixed meal after a previous high-fat meal has been shown to elicit a peak in plasma TGs before the absorption of lipid from the current meal.[@bib20] Glucose ingestion 5 hours after a high-fat meal decreases lipid stores in human enterocytes.[@bib9] In healthy men, under the conditions of constant intraduodenal feeding and a pancreatic clamp, subcutaneous injection of GLP-2 caused a rapid and transient increase in plasma TGs and TRL particles.[@bib19] In the latter study we showed that GLP-2 mobilized lipid that was ingested 7 hours earlier, which likely was retained in 1 or more of the earlier-mentioned intestinal lipid pools.[@bib19] Furthermore, sham fat feeding was shown to stimulate CM secretion, suggesting the involvement of a neural regulatory pathway in intestinal lipid mobilization.[@bib8] Collectively, mounting evidence supports the existence of TG stores in the human intestine that are subject to release in response to certain stimuli. However, the specific mechanism(s) by which mobilization of intestinal TG stores occurs remain unclear.

The goal of this study was to investigate the mechanism by which oral glucose mobilizes TGs stored within enterocytes in human beings and to identify the specific lipid pools that are mobilized. In each experiment, participants ingested a high-fat liquid meal and, 5 hours later, ingested glucose or water. In aim 1, in vivo circulating lipid responses to oral glucose were examined. In aim 2, duodenal biopsy specimens were obtained and ultrastructural and molecular responses were characterized.

Results {#sec1}
=======

Oral Glucose Ingested 5 Hours After a High-Fat Liquid Meal Acutely Increases Plasma TG Concentration {#sec1.1}
----------------------------------------------------------------------------------------------------

Lipid responses to oral glucose and water were measured in 6 healthy participants ([Table 1](#tbl1){ref-type="table"}) in a study design illustrated in [Figure 1](#fig1){ref-type="fig"}*A*. As anticipated in aim 1, plasma glucose levels increased in response to the ingestion of glucose, but not water ([Figure 1](#fig1){ref-type="fig"}*B*). After glucose ingestion, plasma insulin levels also increased from a basal level of approximately 30 pmol/L to peak at approximately 150 pmol/L at 30 minutes, followed by a gradual decline to basal level 2 hours later ([Figure 1](#fig1){ref-type="fig"}*C*). In both groups plasma TGs increased to a postprandial peak at approximately 3 hours after fat ingestion before decreasing toward baseline ([Figure 1](#fig1){ref-type="fig"}*D*). With water ingestion, the decrease in plasma TGs continued unabated and approached basal levels at approximately 7 hours. However, after glucose ingestion, plasma TGs plateaued during the following 2 hours (*P* = .024 glucose vs water).Table 1Demographics and Biochemical Characteristics of Aim 1 ParticipantsSubjectAge, *y*Weight, *kg*Height, *cm*BMI, *kg/m*^*2*^Waist, *cm*Fasting glucose level, *mmol/L*Fasting TG level, *mmol/L*Fasting insulin level, *pmol/L*158721782395.55.60.763524677166271014.90.734834687182261004.50.97374537617225.7874.91.99945298718226.4944.40.6836.56578417926884.50.5929Means48.280.5176.525.794.34.81.046.6SE4.42.62.60.62.40.20.29.8[^1]Figure 1**Lipid responses to oral glucose ingestion.** (*A*) Study design. After an overnight fast, subjects ingested a high-fat liquid meal and 5 hours later ingested a glucose solution or equivalent volume of water in 2 randomized visits. (*B*) Blood glucose and (*C*) insulin concentrations during the study period. (*D*) TG concentrations in plasma during the study period, expressed as a percentage of baseline. (*E--G*) TG concentrations in total TRL, CM-sized TRL, and VLDL-sized TRL 2 hours after glucose or water ingestion, expressed as the percentage of levels at t = 5 hours. *Arrows* indicate time of glucose or water ingestion. All *P* values were with repeated-measures analysis of variance between 5 and 7 hours.

Oral Glucose Ingested 5 Hours After a High-Fat Liquid Meal Increased TGs in Total and CM-Sized, but Not in Smaller Very-Low-Density Lipoprotein--Sized, TRL Particles in the Circulation {#sec1.2}
----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Circulating total TRL TG tended to be higher after glucose vs water ingestion (*P* = .091) ([Figure 1](#fig1){ref-type="fig"}*E*). To identify whether large or small TRLs were most responsible for the increase in plasma and TRL TGs after glucose ingestion, TRLs were separated further by ultracentrifugation into larger CM-sized particles (Svedberg flotation \> 400, predominantly comprising CMs) and smaller very-low-density lipoprotein (VLDL)-sized particles (Svedberg flotation 20--400, likely comprising both hepatically derived VLDL particles and smaller, intestinally derived CMs). An increase in TGs in the larger CM-sized TRL particles was observed with glucose ingestion (*P* = .049, analysis of variance) ([Figure 1](#fig1){ref-type="fig"}*F*). Despite interindividual variations, as is the usual case for most human mechanistic studies, the response was statistically significant because each subject showed a response to glucose, either a reversal of the decrease or an attenuated decrease. Changes in the smaller VLDL-sized TRL particles were similar with both glucose and water ingestion (*P* = .340) ([Figure 1](#fig1){ref-type="fig"}*G*). These results suggest that the increase in plasma TGs in response to glucose ingestion was owing exclusively to an increase in CM-sized TRL particles.

Presence of Lipid Pools Within the Intestinal Mucosa {#sec1.3}
----------------------------------------------------

Duodenal biopsy specimens were obtained 1 hour after glucose or water ingestion from 24 participants ([Table 2](#tbl2){ref-type="table"}). Enterocytes within biopsy specimens were subjected to ultrastructural analysis using transmission electron microscopy. Consistent with previous observations, the duodenal samples obtained 6 hours after fat ingestion contained considerable quantities of lipids both intracellularly and extracellularly ([Figure 2](#fig2){ref-type="fig"}*A*). Within enterocytes, lipids were observed in large CLDs ([Figure 2](#fig2){ref-type="fig"}*B*), in smaller lipid droplets within the endoplasmic reticulum (ER) ([Figure 2](#fig2){ref-type="fig"}*C*), and within the Golgi ([Figure 2](#fig2){ref-type="fig"}*D*). In addition, secreted CMs were present in the intercellular spaces between enterocytes. Overall, the enterocyte ultrastructure and lipid pools observed in human duodenal enterocytes appeared similar to what has been observed previously in mice.[@bib12]Table 2Demographics of Aim 2 ParticipantsGlucosePlaceboN1212BMI, *kg/m*^*2*^25.3 ± 0.925.5 ± 1.5Age, *y*34.6 ± 2.934.7 ± 3.1Sex4 M/8 F2 M/10 F[^2][^3]Figure 2**Lipid pools within the intestinal mucosa.** (*A*) A transmission electron microscopy image of an enterocyte from a duodenal biopsy specimen obtained 6 hours after a high-fat liquid meal and 1 hour after glucose ingestion. Lipid present within CLDs is shown (*asterisk*), as well as in secreted CMs in the intercellular space (*white plus symbol*). (*B*) An enterocyte containing lipid within several large CLDs (*asterisk*). (*C*) An enterocyte containing lipid within smaller lipid droplets in the ER, which are surrounded by a bilayer membrane and usually are observed at the apical side of the cell. (*D*) Lipid present within the Golgi of an enterocyte, which normally was observed above the nucleus. *Scale bars*: 1 μm (*A*, *B*, and *D*), and 0.5 μm (*C*).

Oral Glucose Mobilizes Enterocyte CLD Stores {#sec1.4}
--------------------------------------------

We performed quantitative analyses of enterocyte CLDs in duodenal biopsy specimens obtained in a design similar to that of aim 1 ([Figure 3](#fig3){ref-type="fig"}*A*). After glucose and water ingestion, 34% and 44% of enterocytes per biopsy sample contained CLDs, respectively ([Figure 3](#fig3){ref-type="fig"}*B*) (*P* = .14). In the samples containing CLDs, there were fewer CLDs per cell in response to glucose compared with water ([Figure 3](#fig3){ref-type="fig"}*C*) (*P* = .02). Although the average diameters (*P* = .18) and areas (*P* = .17) of individual CLDs were not significantly different between treatments (data not shown), there were differences in the CLD diameter distributions, with more CLDs falling into the smaller size ranges and fewer into larger size ranges after glucose compared with water ingestion ([Figure 3](#fig3){ref-type="fig"}*D*) (*P* = .03). However, the difference between treatments in total CLD area per enterocyte did not reach statistical significance ([Figure 3](#fig3){ref-type="fig"}*E*) (*P* = .11). We also assessed the amount of lipids within the secretory pathway in enterocytes, which included lipids in the ER, Golgi, and Golgi-derived secretory vesicles. There were no significant differences in the proportion of biopsy specimens containing low, moderate, and high amounts of secretory lipids in response to glucose compared with water ingestion ([Figure 3](#fig3){ref-type="fig"}*F*) (*P* = .29, Fisher exact test). Taken together, glucose ingestion resulted in fewer CLDs in enterocytes and a shift toward smaller-sized CLDs.Figure 3**Oral glucose mobilizes enterocyte CLD stores.** (*A*) Study design. Enterocyte CLD and secretory lipid stores were analyzed 6 hours after a high-fat liquid meal and 1 hour after glucose or water ingestion (N = 12 patients per group). (*B*) Percentage of enterocytes containing CLDs (*P* = .14, *t* test). (*C*) Average CLD number per cell (*P* = .022, *t* test). (*D*) CLD diameter distribution (*P* = .03, Kolmogorov--Smirnov test) and (*E*) average total CLD area per cell (*P* = .11, *t* test). (*F*) Amount of lipid within the secretory pathway (includes lipid in ER, Golgi, and secretory vesicles) (*P* = .29 Fisher exact test).

Oral Glucose Does Not Mobilize Lipids Within Enterocytes After Delayed Fasting {#sec1.5}
------------------------------------------------------------------------------

To investigate whether glucose mobilization of intestinal lipid stores persists after more prolonged fasting, a separate group of subjects ([Table 3](#tbl3){ref-type="table"}) ingested glucose or water 9 hours after the high-fat liquid meal. Duodenal biopsy specimens were collected 1 hour later (10 hours after ingesting the high-fat liquid meal). Under these conditions, no stimulatory effect of glucose on lipid mobilization was observed. There were no significant differences in the percentage of cells with CLDs, CLD number or size, or in the amount of lipids within the secretory pathway in enterocytes in response to glucose compared with water ingestion ([Figure 4](#fig4){ref-type="fig"}). This likely was owing to a lower proportion of enterocytes containing CLDs after prolonged fasting compared with the 6-hour fast ([Figure 5](#fig5){ref-type="fig"}). Thus, mobilization of enterocyte CLDs by oral glucose appears to depend on the presence of a sufficient pool of intestinal lipid stores retained in the enterocyte after fat ingestion.Table 3Demographics of Additional Participants Participating in Aim 2 With Delayed FastingGlucosePlaceboN55BMI, *kg/m*^*2*^23.8 ± 1.222.2 ± 1.4Age, *y*33.0 ± 3.833.6 ± 3.2Sex1 M/4 F1 M/4 F[^4][^5]Figure 4**Analysis of enterocyte lipid stores in response to glucose or water ingestion after a delayed fast.** (*A*) Study design. Duodenal biopsy specimens were obtained 10 hours after ingestion of a high-fat liquid meal and 1 hour after ingestion of glucose or water. (*B*) Percentage of enterocytes containing CLDs (*P* = .45). (*C*) Average CLD number per cell (*P* = .28). (*D*) CLD diameter distribution and (*E*) average total CLD area per cell (*P* = .18). (*F*) Amount of lipid within the secretory pathway (includes lipid in ER, Golgi, and secretory vesicles) (*P* = 1, Fisher exact test). Average CLD number and total CLD area per cell were compared with a *t* test.Figure 5**Comparison of enterocyte lipid stores after different fasting times.** (*A*) Percentage of cells containing CLDs (*P* = .025) and (*B*) amount of lipid within the secretory pathway (*P* = .15, Fisher exact test) in individuals at 6 hours compared with 10 hours after the high-fat liquid meal (and 1 h after water consumption). \**P* \< .05, *t* test.

Differential Expression of Proteins in Duodenal Biopsy Specimens From Subjects Administered Glucose or Water After a High-Fat Liquid Meal {#sec1.6}
-----------------------------------------------------------------------------------------------------------------------------------------

Untargeted proteomic analysis of duodenal biopsy specimens identified 2919 proteins, with 2900 present in both water and glucose ingestion conditions, only 9 were identified in response to glucose and only 10 were identified in response to water ingestion ([Figure 6](#fig6){ref-type="fig"}*A*). A total of 48 of these proteins were present at relatively lower levels and 86 were present at relatively higher levels in response to glucose compared with water ([Table 4](#tbl4){ref-type="table"}). After correction for multiple statistical tests, the relative levels of 7 proteins remained significantly different between treatments.Figure 6**Proteins present in duodenal biopsy specimens from subjects administered glucose or water after a high-fat liquid meal.** Duodenal biopsy specimens were collected 6 hours after lipid and 1 hour after glucose or water ingestion from patients undergoing a diagnostic endoscopy (N = 12 patients per group). (*A*) Venn diagram of proteins identified in response to glucose or water ingestion. Proteins present in at least 3 samples in 1 group and 0 samples in the other group were considered present in only 1 group. Proteins identified in at least 3 samples in 1 group and at least 1 sample in the other group were considered present in both groups. (*B*) Percentage of proteins within broad functional groups that were present at either relatively lower (48 total proteins) or relatively higher (86 total proteins) levels in response to glucose compared with water ingestion, as classified based on their biological/molecular functions. Only proteins that were identified in at least 3 samples in both groups and present at relatively different levels (*P* \< .05, *t* test), or at least 3 samples in 1 group and 0 samples in the other group, were included in this classification. A Database for Annotation, Visualization, and Integrated Discovery search of the 2919 identified proteins resulted in the identification of 270 proteins with GO terms related to lipid metabolism. (*C*) Percentage of the 270 lipid metabolism-related proteins involved in more specific lipid-related functions. (*D*) String analysis of the 270 lipid metabolism-related proteins. The thickness of the *line* represents the strength of evidence of a structural/functional relationship between 2 proteins. Cluster 1 is enriched in proteins involved in TG and phospholipid (PL) synthesis and metabolism, cluster 2 is enriched in proteins involved in lipoprotein metabolism, cluster 3 is enriched in proteins involved in cholesterol/steroid metabolism, and cluster 4 is enriched in proteins involved in FA modification/metabolism/transport. Proteins that were present at relatively different levels in response to glucose compared with water consumption (*P* \< .05, *t* test) are *circled in red*. TAG, triacylglycerol.Table 4Proteins Present at Relatively Different Levels in Duodenal Biopsy Specimens From Subjects Administered Glucose or Water After a High-Fat Liquid MealUniprot accessionProtein nameGene nameFold change*t* test *P* valueFunctionP05997Collagen α-2(V) chain[a](#tbl4fna){ref-type="table-fn"}COL5A2-7.4957.0030Other (extracellular matrix protein)Q5T5C0Syntaxin-binding protein 5[a](#tbl4fna){ref-type="table-fn"}STXBP5-6.86284.72E-22Protein folding/transportQ8N2S1Latent-transforming growth factor β-binding protein 4[a](#tbl4fna){ref-type="table-fn"}LTBP4-6.7854.0002Protein folding/transportO14672Disintegrin and metalloproteinase domain-containing protein 10[a](#tbl4fna){ref-type="table-fn"}ADAM10-6.7264.0010Protein metabolismP17480Nucleolar transcription factor 1[a](#tbl4fna){ref-type="table-fn"}UBTF-6.2100.0063Transcription/RNA processing/translationQ8N8S7Protein enabled homolog[a](#tbl4fna){ref-type="table-fn"}ENAH-5.7620.0007CytoskeletonQ7Z6K5Arpin[a](#tbl4fna){ref-type="table-fn"}ARPIN-5.75732.02E-19CytoskeletonQ9UQ35Serine/arginine repetitive matrix protein 2[a](#tbl4fna){ref-type="table-fn"}SRRM2-5.5687.0002Transcription/RNA processing/translationP49790Nuclear pore complex protein Nup153[a](#tbl4fna){ref-type="table-fn"}NUP153-5.1794.0079Transcription/RNA processing/translationQ9NRG7Epimerase family protein SDR39U1[a](#tbl4fna){ref-type="table-fn"}SDR39U1-4.11423.26E-28Mitochondria/redoxP16403Histone H1.2HIST1H1C-1.0513.0213HistoneP01860Immunoglobulin heavy constant γ 3IGHG3-1.0063.0007Immune responseP13284γ-interferon--inducible lysosomal thiol reductaseIFI30-1.0048.0116Mitochondria/redoxP35580Myosin-10MYH10-0.9176.0449CytoskeletonP08590Myosin light chain 3MYL3-0.8947.0464Other (regulation of muscle contraction)Q71UI9Histone H2A.VH2AFV-0.8933.0072HistoneQ71DI3Histone H3.2-0.8572.0338HistoneA0A0B4J1X5Immunoglobulin heavy variable 3--74IGHV3-74-0.8112.0076Immune responseQ99829Copine-1CPNE1-0.7877.0101Transcription/RNA processing/translationP01780Immunoglobulin heavy variable 3--7IGHV3-7-0.7127.0154Immune responseP42167Lamina-associated polypeptide 2; isoforms β/γTMPO-0.6933.0453Cell--cell adhesionP0CG06Immunoglobulin λ constant 2IGLC2-0.6852.0260Immune responseQ96KA5Cleft lip and palate transmembrane protein 1--like proteinCLPTM1L-0.6539.0031Other (apoptosis)P01859Immunoglobulin heavy constant γ 2IGHG2-0.6532.0234Immune responseP84243Histone H3.3H3F3A-0.6487.0236HistoneQ8IUX7Adipocyte enhancer-binding protein 1AEBP1-0.637.0226Transcription/RNA processing/translationQ09666Neuroblast differentiation-associated protein AHNAKAHNAK-0.635.0397Cell--cell adhesionQ9BY50Signal peptidase complex catalytic subunit SEC11CSEC11C-0.6182.0288Protein metabolismP07305Histone H1.0H1F0-0.5824.0446HistoneP01857Immunoglobulin heavy constant γ 1IGHG1-0.5542.0206Immune responseQ9UEW8STE20/SPS1-related proline-alanine--rich protein kinaseSTK39 SPAK-0.5436.0033KinaseP30405Peptidyl-prolyl cis-trans isomerase F; mitochondrialPPIF-0.5252.0168Protein folding/transportP563786.8-kilodalton mitochondrial proteolipidMP68-0.4738.0418Mitochondria/redoxP61758Prefoldin subunit 3VBP1-0.4401.0427Protein folding/transportQ96L92Sorting nexin-27SNX27-0.427.0158Protein folding/transportO75323Protein NipSnap homolog 2GBAS-0.4059.0315Mitochondria/redoxO75190DnaJ homolog subfamily B member 6DNAJB6-0.3578.0384Protein folding/transportQ86UP2KinectinKTN1-0.3174.0401Cell--cell adhesionQ15629Translocating chain-associated membrane protein 1TRAM1-0.3048.0452Protein folding/transportQ9BWS9Chitinase domain-containing protein 1CHID1-0.2768.0223Immune responseO00186Syntaxin-binding protein 3STXBP3-0.2611.0332Protein folding/transportQ0254360S ribosomal protein L18aRPL18A-0.2238.0089Transcription/RNA processing/translationP13861cAMP-dependent protein kinase type II-α regulatory subunitPRKAR2A-0.217.0098KinaseP84085ADP-ribosylation factor 5ARF5-0.1788.0354Protein folding/transportP28482Mitogen-activated protein kinase 1MAPK1-0.1528.0078KinaseP59998Actin-related protein 2/3 complex subunit 4ARPC4-0.1477.0141CytoskeletonO15145Actin-related protein 2/3 complex subunit 3ARPC3-0.145.0464CytoskeletonQ5VTE0Putative elongation factor 1-α--like 3EEF1A1P5-0.134.0151Transcription/RNA processing/translationQ8IZ83Aldehyde dehydrogenase family 16 member A1ALDH16A10.1539.0433Mitochondria/redoxQ96A33Coiled-coil domain-containing protein 47CCDC470.1676.0403Other (calcium ion homeostasis, ERAD)Q9NPA0ER membrane protein complex subunit 7EMC70.1744.0474Other (carbohydrate binding)Q15417Calponin-3CNN30.1993.0488CytoskeletonP21281V-type proton ATPase subunit B; brain isoformATP6V1B20.2023.0460Ion transportP4855626S proteasome non-ATPase regulatory subunit 8PSMD80.209.0347Protein metabolismO14734Acyl-coenzyme A thioesterase 8ACOT80.2101.0177Lipid metabolismQ9NS69Mitochondrial import receptor subunit TOM22 homologTOMM220.2105.0281Mitochondria/redoxP11940Polyadenylate-binding protein 1PABPC10.2111.0441Transcription/RNA processing/translationP78344Eukaryotic translation initiation factor 4 γ 2EIF4G20.2114.0490Transcription/RNA processing/translationQ14974Importin subunit β-1KPNB10.2177.0417Protein folding/transportQ1320026S proteasome non-ATPase regulatory subunit 2PSMD20.2182.0108Protein metabolismO95782AP-2 complex subunit α-1AP2A10.219.0059Protein folding/transportQ93034Cullin-5CUL50.2198.0058Protein metabolismQ9UNZ2NSFL1 cofactor p47NSFL1C0.2214.0150Protein metabolismQ9BTM9Ubiquitin-related modifier 1URM10.2221.0047Transcription/RNA processing/translationO75436Vacuolar protein sorting-associated protein 26AVPS26A0.2305.0230Protein folding/transportP25788Proteasome subunit α type-3PSMA30.2323.0358Protein metabolismQ9Y2Z0Protein SGT1 homologSUGT10.2356.0128Protein metabolismQ9P2J5Leucine-tRNA ligase; cytoplasmicLARS0.2405.0207Transcription/RNA processing/translationP38606V-type proton ATPase catalytic subunit AATP6V1A0.2418.0123Ion transportQ93008Probable ubiquitin carboxyl-terminal hydrolase FAF-XUSP9X0.2423.0467Protein metabolismP11142Heat shock cognate 71-kilodalton proteinHSPA80.253.0051Protein folding/transportP55060Exportin-2CSE1L0.2541.0385Protein folding/transportO75146Huntingtin-interacting protein 1--related proteinHIP1R0.259.0285CytoskeletonO96008Mitochondrial import receptor subunit TOM40 homologTOMM400.2593.0076Mitochondria/redoxP15531Nucleoside diphosphate kinase ANME10.271.0213KinaseP46734Dual-specificity mitogen-activated protein kinase kinase 3MAP2K30.2752.0373KinaseP28070Proteasome subunit β type-4PSMB40.2764.0158Protein MetabolismO75381Peroxisomal membrane protein PEX14PEX140.2803.0238Protein folding/transportQ9NUQ8ATP-binding cassette subfamily F member 3ABCF30.2846.0347Cell--cell adhesionQ9Y697Cysteine desulfurase; mitochondrialNFS10.2919.0167Protein metabolismQ02790Peptidyl-prolyl cis-trans isomerase FKBP4FKBP40.2953.0477Protein folding/transportQ15020Squamous cell carcinoma antigen recognized by T cell 3SART30.3007.0457Transcription/RNA processing/translationQ01813ATP-dependent 6-phosphofructokinase; platelet typePFKP0.3087.0367Carbohydrate metabolismQ5H9R7Serine/threonine-protein phosphatase 6 regulatory subunit 3PPP6R30.3154.0231Protein metabolismO95433Activator of 90-kilodalton heat shock protein ATPase homolog 1AHSA10.3177.0091Protein folding/transportO0023126S proteasome non-ATPase regulatory subunit 11PSMD110.3221.0158Protein metabolismP31689DnaJ homolog subfamily A member 1DNAJA10.3234.0479Protein folding/transportO75915PRA1 family protein 3ARL6IP50.3236.0439CytoskeletonQ9ULA0Aspartyl aminopeptidaseDNPEP0.3283.0271Protein metabolismQ99757Thioredoxin; mitochondrialTXN20.3371.0343Mitochondria/redoxQ9NTX5Ethylmalonyl-CoA decarboxylaseECHDC10.341.0450Lipid metabolismQ96GK7Fumarylacetoacetate hydrolase domain-containing protein 2AFAHD2A0.35.0195Other (potential hydrolase)Q9Y3D928S ribosomal protein S23; mitochondrialMRPS230.3593.0114Transcription/RNA processing/translationP23526AdenosylhomocysteinaseAHCY0.3976.0216Other (regulation of methylation)P18827Syndecan-1SDC10.4174.0314Other (cell migration)P08621U1 small nuclear ribonucleoprotein 70 kilodaltonsSNRNP700.4216.0144Transcription/RNA processing/translationP28838Cytosol aminopeptidaseLAP30.4431.0436Protein metabolismQ9NR19Acetyl-coenzyme A synthetase; cytoplasmicACSS20.4512.0470Lipid metabolismQ8N5G0Small integral membrane protein 20SMIM200.4532.0296Mitochondria/redoxP49247Ribose-5-phosphate isomeraseRPIA0.4698.0326Carbohydrate metabolismQ9Y333U6 snRNA-associated Sm-like protein LSm2LSM20.4741.0355Transcription/RNA processing/translationQ9H490Phosphatidylinositol glycan anchor biosynthesis class U proteinPIGU0.4799.0487Lipid metabolismO75382Tripartite motif-containing protein 3TRIM30.485.0174Immune responseQ151253-β-hydroxysteroid-Δ(8); Δ(7)-isomeraseEBP0.4859.0413Lipid metabolismQ16881Thioredoxin reductase 1; cytoplasmicTXNRD10.4905.0148Mitochondria/redoxP07108Acyl-CoA binding proteinDBI0.4917.0382Lipid metabolismP48637Glutathione synthetaseGSS0.4944.0440Other (glutathione synthesis)O76003Glutaredoxin-3GLRX30.4953.0403Mitochondria/redoxQ12882Dihydropyrimidine dehydrogenase \[NADP(+)\]DPYD0.5076.0165Mitochondria/redoxQ9NWU539S ribosomal protein L22; mitochondrialMRPL220.526.0101Transcription/RNA processing/translationQ9NVS9Pyridoxine-5\'-phosphate oxidasePNPO0.5395.0337Mitochondria/redoxQ9UHY7Enolase-phosphatase E1ENOPH10.5544.0307Protein metabolismP16930FumarylacetoacetaseFAH0.5694.0236Protein metabolismP48506Glutamate-cysteine ligase catalytic subunitGCLC0.5745.0241Mitochondria/redoxQ8N98339S ribosomal protein L43; mitochondrialMRPL430.5932.0266Transcription/RNA processing/translationQ9UBM77-dehydrocholesterol reductaseDHCR70.6045.0283Lipid metabolismP48147Prolyl endopeptidasePREP0.6099.0244Protein metabolismP8267328S ribosomal protein S35; mitochondrialMRPS350.6118.0363Transcription/RNA processing/translationQ8WVX9Fatty acyl-CoA reductase 1FAR10.6231.0223Lipid metabolismQ9Y679Ancient ubiquitous protein 1AUP10.6292.0093Protein metabolismP37840α-synucleinSNCA0.6332.0063Mitochondria/redoxQ9BRF8Serine/threonine-protein phosphatase CPPED1CPPED10.6702.0313Protein metabolismQ6UX53Methyltransferase-like protein 7BMETTL7B0.7067.0210Other (probable methyltransferase)P02792Ferritin light chainFTL0.8169.0124Ion transportP02794Ferritin heavy chainFTH10.8959.0144Mitochondria/redoxQ9BVL4Selenoprotein O[b](#tbl4fnb){ref-type="table-fn"}SELENOO5.0987.0002Mitochondria/redoxQ9HB07UPF0160 protein MYG1; mitochondrial[b](#tbl4fnb){ref-type="table-fn"}C12orf105.98435.8E-16Mitochondria/redoxP2209040S ribosomal protein S4[b](#tbl4fnb){ref-type="table-fn"}RPS4Y16.7537.0018Transcription/RNA processing/translationQ9P003Protein cornichon homolog 4[b](#tbl4fnb){ref-type="table-fn"}CNIH47.16181.74E-15Protein folding/transportO60938Keratocan[b](#tbl4fnb){ref-type="table-fn"}KERA7.4582.0050Other (keratan sulfate metabolism/cornea development)Q9C0D9Ethanolaminephosphotransferase 1[b](#tbl4fnb){ref-type="table-fn"}SELENOI7.4638.0005Lipid metabolismQ96HV5Transmembrane protein 41A[b](#tbl4fnb){ref-type="table-fn"}TMEM41A7.5997.0023Other (transmembrane protein)P62306Small nuclear ribonucleoprotein F[b](#tbl4fnb){ref-type="table-fn"}SNRPF7.78473.21E-17Transcription/RNA processing/translationQ8NDA2Hemicentin-2[b](#tbl4fnb){ref-type="table-fn"}HMCN211.52043.81E-16Immune response[^6][^7][^8][^9]

The differentially expressed proteins (defined as *P* \< .05 between treatment groups) were classified into broad groups based on gene ontology (GO) terms for biological processes and molecular functions ([Table 5](#tbl5){ref-type="table"}, [Figure 6](#fig6){ref-type="fig"}*B*). Among the 48 proteins present at relatively lower levels in response to glucose, protein folding/transport (19%), immune response (15%), and transcription/RNA processing/translation (15%) were the most abundant functions. Of the 86 proteins present at relatively higher levels in response to glucose, those involved in protein metabolism (21%), mitochondria/redox (16%), and transcription/RNA processing/translation (15%) were the most abundant. Interestingly, in response to glucose compared with water ingestion, histone proteins were present at relatively lower levels, while those involved in carbohydrate metabolism, ion transport, and lipid metabolism all were present at relatively higher levels.Table 5GO Terms Associated With Lipid Metabolism-Related Proteins Present in Duodenal Biopsy Specimens 6 Hours After a High-Fat Liquid MealCholesterol/steroid metabolism UP_KEYWORDSCholesterol biosynthesis GOTERM_BP_DIRECTCholesterol biosynthetic process UP_KEYWORDSCholesterol metabolism UP_KEYWORDSSteroid biosynthesis KEGG_PATHWAYSteroid hormone biosynthesis UP_KEYWORDSSteroid metabolism UP_KEYWORDSSterol biosynthesis GOTERM_MF_DIRECTSterol esterase activity UP_KEYWORDSSterol metabolismCLD storage/metabolism GOTERM_CC_DIRECTLipid droplet GPTERM_BP_DIRECTLipid storage CM trafficking GOTERM_CC_DIRECTCOPII vesicle coat GOTERM_CC_DIRECTER to Golgi transport vesicle membrane GOTERM_MF_DIRECTSNARE binding GOTERM_CC_DIRECTSNARE complex GOTERM_BP_DIRECTVesicle fusionEicosanoid metabolism UP_KEYWORDSLeukotriene biosynthesis GOTERM_BP_DIRECTLeukotriene biosynthetic process GOTERM_BP_DIRECTLeukotriene metabolic process GOTERM_BP_DIRECTProstaglandin biosynthetic processFA modification/metabolism/transport GOTERM_BP_DIRECTFatty acid biosynthetic process GOTERM_MF_DIRECT3-hydroxyacyl-CoA dehydrogenase activity INTERPRO3-hydroxyacyl-CoA dehydrogenase, conserved site INTERPRO3-hydroxyacyl-CoA dehydrogenase, C-terminal INTERPRO3-hydroxyacyl-CoA dehydrogenase, NAD binding GOTERM_MF_DIRECTAcyl-CoA dehydrogenase activity INTERPROAcyl-CoA dehydrogenase, conserved site INTERPROAcyl-CoA dehydrogenase/oxidase INTERPROAcyl-CoA dehydrogenase/oxidase C-terminal INTERPROAcyl-CoA dehydrogenase/oxidase, N-terminal GOTERM_MF_DIRECTAcyl-CoA hydrolase activity GOTERM_BP_DIRECTAcyl-CoA metabolic process INTERPROAcyl-CoA oxidase PIR_SUPERFAMILYAcyl-CoA oxidase INTERPROAcyl-CoA oxidase, C-terminal INTERPROAcyl-CoA oxidase/dehydrogenase, central domain INTERPROAMP binding, conserved site INTERPROAMP-dependent synthetase/ligase GOTERM_MF_DIRECTDecanoate-CoA ligase activity INTERPRODomain of unknown function DUF4009 GOTERM_BP_DIRECTFatty acid β-oxidation GOTERM_BP_DIRECTFatty acid β-oxidation using acyl-CoA dehydrogenase GOTERM_BP_DIRECTFatty acid β-oxidation using acyl-CoA oxidase KEGG_PATHWAYFatty acid biosynthesis KEGG_PATHWAYFatty acid degradation GOTERM_BP_DIRECTFatty acid elongation GOTERM_BP_DIRECTFatty acid metabolic process KEGG_PATHWAYFatty acid metabolism GOTERM_BP_DIRECTFatty acid transport GOTERM_MF_DIRECTFatty-acyl-CoA binding GOTERM_BP_DIRECTFatty-acyl-CoA biosynthetic process GOTERM_BP_DIRECTLipid homeostasis GOTERM_BP_DIRECTLong-chain fatty acid import GOTERM_BP_DIRECTLong-chain fatty acid metabolic process GOTERM_MF_DIRECTLong-chain fatty acid-CoA ligase activity GOTERM_BP_DIRECTLong-chain fatty-acyl-CoA biosynthetic process GOTERM_BP_DIRECTLong-chain fatty-acyl-CoA metabolic process GOTERM_MF_DIRECTVery long-chain fatty acid-CoA ligase activityLipid binding proteins INTERPROAcyl-CoA-binding protein, ACBP INTERPROAcyl-CoA-binding protein, ACBP, conserved site INTERPROCytosolic fatty-acid binding UP_SEQ_FEATUREDomain: ACB INTERPROLipocalin/cytosolic fatty-acid binding protein domain INTERPROLipocalin/cytosolic fatty-acid binding protein domain GOTERM_MF_DIRECTRetinal binding GOTERM_MF_DIRECTRetinoic acid binding GOTERM_MF_DIRECTRetinoid binding GOTERM_MF_DIRECTRetinol binding UP_KEYWORDSRetinol binding UP_KEYWORDSRetinol binding UP_KEYWORDSVitamin ALipoprotein metabolism INTERPROApolipoprotein A1/A4/E GOTERM_MF_DIRECTCholesterol binding GOTERM_BP_DIRECTCholesterol efflux GOTERM_BP_DIRECTCholesterol homeostasis GOTERM_BP_DIRECTCholesterol metabolic process GOTERM_MF_DIRECTCholesterol transporter activity GOTERM_CC_DIRECTChylomicron UP_KEYWORDSChylomicron GOTERM_BP_DIRECTChylomicron remnant clearance UP_KEYWORDSHDL GOTERM_CC_DIRECTHigh-density lipoprotein particle GOTERM_BP_DIRECTHigh-density lipoprotein particle assembly GOTERM_BP_DIRECTHigh-density lipoprotein particle clearance GOTERM_MF_DIRECTHigh-density lipoprotein particle receptor binding GOTERM_BP_DIRECTHigh-density lipoprotein particle remodeling GOTERM_CC_DIRECTIntermediate-density lipoprotein particle UP_KEYWORDSLDL SMARTLDLa GOTERM_MF_DIRECTLipase inhibitor activity UP_KEYWORDSLipid transport GOTERM_BP_DIRECTLipid transport GOTERM_MF_DIRECTLipid transporter activity GOTERM_BP_DIRECTLipoprotein biosynthetic process GOTERM_BP_DIRECTLipoprotein metabolic process INTERPROLDL-receptor class A repeat INTERPROLDL-receptor class A, conserved site GOTERM_CC_DIRECTLDL particle GOTERM_BP_DIRECTLDL particle remodeling GOTERM_BP_DIRECTNegative regulation of cholesterol transport GOTERM_BP_DIRECTNegative regulation of lipid catabolic process GOTERM_BP_DIRECTNegative regulation of lipid metabolic process GOTERM_BP_DIRECTNegative regulation of receptor-mediated endocytosis GOTERM_BP_DIRECTNegative regulation of VLDL particle clearance GOTERM_BP_DIRECTNegative regulation of VLDL particle remodeling GOTERM_BP_DIRECTNeuron projection regeneration GOTERM_MF_DIRECTPhosphatidylcholine binding GOTERM_MF_DIRECTPhosphatidylcholine-sterol O-acyltransferase activator activity GOTERM_BP_DIRECTPhospholipid efflux GOTERM_BP_DIRECTPositive regulation of cholesterol esterification GOTERM_BP_DIRECTPositive regulation of fatty acid biosynthetic process GOTERM_BP_DIRECTPositive regulation of lipoprotein lipase activity GOTERM_BP_DIRECTPositive regulation of triglyceride catabolic process GOTERM_BP_DIRECTRegulation of Cdc42 protein signal transduction GOTERM_BP_DIRECTRegulation of intestinal cholesterol absorption GOTERM_BP_DIRECTReverse cholesterol transport GOTERM_CC_DIRECTSpherical HDL particle GOTERM_BP_DIRECTTriglyceride homeostasis GOTERM_CC_DIRECTVLDL particle GOTERM_BP_DIRECTVLDL particle remodeling UP_KEYWORDSVLDLTAG and PL synthesis/metabolism GOTERM_MF_DIRECT1-acylglycerol-3-phosphate O-acyltransferase activity GOTERM_BP_DIRECTAcylglycerol catabolic process GOTERM_MF_DIRECTAcylglycerol lipase activity GOTERM_BP_DIRECTCDP-diacylglycerol biosynthetic process GOTERM_BP_DIRECTEther lipid biosynthetic process GOTERM_BP_DIRECTGlycerolipid metabolic process GOTERM_BP_DIRECTGlycerophospholipid biosynthetic process GOTERM_BP_DIRECTGlycerophospholipid catabolic process KEGG_PATHWAYGlycerophospholipid metabolism GOTERM_BP_DIRECTGPI anchor biosynthetic process GOTERM_MF_DIRECTLysophospholipase activity GOTERM_BP_DIRECTPhosphatidic acid biosynthetic process UP_KEYWORDSPhospholipid biosynthesis GOTERM_BP_DIRECTPhospholipid biosynthetic process GOTERM_BP_DIRECTPhospholipid catabolic process GOTERM_BP_DIRECTPhospholipid metabolic process UP_KEYWORDSPhospholipid metabolism GOTERM_BP_DIRECTPhospholipid transport INTERPROPhospholipid/glycerol acyltransferase SMARTPlsC UP_SEQ_FEATUREShort sequence motif: HXXXXD motif GOTERM_BP_DIRECTTriglyceride biosynthetic process GOTERM_MF_DIRECTTriglyceride lipase activity[^10]

Because our goal was to identify mechanisms by which intestinal lipid stores are mobilized in response to glucose ingestion, we then specifically examined lipid metabolism-related proteins. Of the 2919 proteins identified, 270 (9%) are known to be involved in lipid/lipoprotein metabolism and transport. The majority of these proteins are involved in FA modification, metabolism, and transport (32%, cluster 4) and lipoprotein metabolism (23%, cluster 2); however, proteins involved in cholesterol/steroid metabolism (cluster 3), TG/phospholipid metabolism (cluster 1), lipid binding, eicosanoid metabolism, CLD storage/metabolism, and CM trafficking also were identified ([Figure 6](#fig6){ref-type="fig"}*C* and *D*). In response to glucose compared with water ingestion, 9 of these lipid-related proteins were present at relatively higher levels (*P* \< .05) ([Table 6](#tbl6){ref-type="table"}). Of note, ethanolaminephosphotransferase 1 was identified only in response to glucose ingestion.Table 6Lipid Metabolism Proteins Present at Relatively Different Levels in Duodenal Biopsy Specimens From Subjects Administered Glucose or Water After a High-Fat Liquid MealUniprot accessionProtein nameGene nameFold change*t* test *P* valueLipid metabolism-related functionO14734Acyl-coenzyme A thioesterase 8ACOT80.2101.0177FA modification/ metabolism/transportQ9NTX5Ethylmalonyl-CoA decarboxylaseECHDC10.341.0450FA modification/ metabolism/transportQ9NR19Acetyl-coenzyme A synthetase; cytoplasmicACSS20.4512.0470FA modification/ metabolism/transportQ9H490Phosphatidylinositol glycan anchor biosynthesis class U proteinPIGU0.4799.0487TAG and PL synthesis/metabolismQ151253-β-hydroxysteroid-Δ(8); Δ(7)-isomeraseEBP0.4859.0413Cholesterol/steroid metabolismP07108Acyl-CoA-binding proteinDBI0.4917.0382Lipid binding proteinQ9UBM77-dehydrocholesterol reductaseDHCR70.6045.0283Cholesterol/steroid metabolismQ8WVX9Fatty acyl-CoA reductase 1FAR10.6231.0223FA modification/metabolism/transportQ9C0D9Ethanolaminephosphotransferase 1[a](#tbl5fna){ref-type="table-fn"}SELENOI7.4638.0005TAG and PL synthesis/metabolism[^11][^12][^13]

A similar comparative proteomic analysis was performed in response to glucose or water ingestion after a longer, overnight fast after the ingestion of a high-fat meal (samples collected 10 hours after a high-fat meal and 1 hour after glucose/water ingestion), in which there were no observed differences in enterocyte CLD stores. This analysis identified 1683 proteins, with 1673 common to both groups, 9 identified only in response to water, and 1 identified only in response to glucose ingestion ([Figure 7](#fig7){ref-type="fig"}*A*). The 96 proteins that were differentially present in this analysis are involved in a variety of cellular processes, with a greater proportion of proteins associated with transcription and translation (GO terms) compared with the initial study ([Tables 7](#tbl7){ref-type="table"} and [8](#tbl8){ref-type="table"}, [Figure 7](#fig7){ref-type="fig"}*B*). The 186 lipid metabolism-related proteins identified in this analysis are involved in similar processes as the initial study ([Figure 7](#fig7){ref-type="fig"}*C* and *D*); however, none of the 6 lipid metabolism proteins that were differentially present in response to glucose compared with water ingestion were the same as those identified at 6 hours after ingesting a high-fat meal ([Table 9](#tbl9){ref-type="table"}).Figure 7**Proteins present in intestinal biopsy specimens from subjects administered glucose or water after an overnight fast after the consumption of a high-fat liquid meal.** Duodenal biopsy specimens were collected 10 hours after lipid and 1 hour after glucose or water ingestion from patients undergoing a diagnostic endoscopy (n = 5 patients per group). (*A*) Venn diagram of proteins identified in response to glucose or water ingestion. Proteins present in at least 3 samples in 1 group and 0 samples in the other group were considered present in only 1 group. Proteins identified in at least 3 samples in 1 group and at least 1 sample in the other group were considered present in both groups. (*B*) Percentage of proteins within broad functional groups that were present at either relatively lower (48 total proteins) or relatively higher (48 total proteins) levels in response to glucose compared with water ingestion, as classified based on their biological/molecular functions. Only proteins that were identified in at least 3 samples in both groups and present at relatively different levels (*P* \< .05, *t* test), or at least 3 samples in 1 group and 0 samples in the other group, were included in this classification. A Database for Annotation, Visualization, and Integrated Discovery search of the 1683 identified proteins resulted in the identification of 186 proteins with GO terms related to lipid metabolism. (*C*) Percentage of the 186 lipid metabolism-related proteins involved in more specific lipid-related functions. (*D*) String analysis of the 186 lipid metabolism-related proteins. The thickness of the *line* represents the strength of evidence of a structural/functional relationship between 2 proteins. Cluster 1 is enriched in proteins involved in FA modification/metabolism/transport, cluster 2 is enriched in proteins involved in lipoprotein metabolism, cluster 3 is enriched in proteins involved in TG and phospholipid (PL) synthesis and metabolism, and cluster 4 is enriched in proteins involved in cholesterol/steroid metabolism. Proteins that were present at relatively different levels (*P* \< .05, *t* test) in response to glucose compared with water ingestion are *circled in red*.Table 7Proteins Present at Relatively Different Levels in Duodenal Biopsy Specimens From Subjects Administered Glucose or Water After an Overnight Fast After the Consumption of a High-Fat Liquid MealUniprot accessionProtein nameGene nameFold change*t* test *P* valueFunctionP02760Protein AMBP[a](#tbl7fna){ref-type="table-fn"}AMBP-10.95862.33E-05Protein metabolismP35613Basigin[a](#tbl7fna){ref-type="table-fn"}BSG-7.47811.28E-05Other (extracellular matrix organization)P42025β-centractin[a](#tbl7fna){ref-type="table-fn"}ACTR1B-6.6073.0003CytoskeletonQ96GA7Serine dehydratase-like[a](#tbl7fna){ref-type="table-fn"}SDSL-6.42384.13E-05Protein metabolismQ9NP81Serine-tRNA ligase; mitochondrial[a](#tbl7fna){ref-type="table-fn"}SARS2-6.4093.0001Transcription/RNA processing/translationQ07837Neutral and basic amino acid transport protein rBAT[a](#tbl7fna){ref-type="table-fn"}SLC3A1-5.9686.0001Protein folding/transportQ9NW15Anoctamin-10[a](#tbl7fna){ref-type="table-fn"}ANO10-5.83176.88E-13Ion transportP33897ATP-binding cassette subfamily D member 1[a](#tbl7fna){ref-type="table-fn"}ABCD1-5.296.0011Lipid metabolismQ9Y320Thioredoxin-related transmembrane protein 2[a](#tbl7fna){ref-type="table-fn"}TMX2-4.7109.0055Mitochondria/redoxP6289960S ribosomal protein L31RPL31-1.4463.0016Transcription/RNA processing/translationP26583High-mobility group protein B2HMGB2-1.3698.0205Transcription/RNA processing/translationP6284140S ribosomal protein S15RPS15-1.339.0217Transcription/RNA processing/translationO43895Xaa-Pro aminopeptidase 2XPNPEP2-1.2009.0161Protein metabolismQ00688Peptidyl-prolyl cis-trans isomerase FKBP3FKBP3-1.1226.0486Protein folding/transportP6242460S ribosomal protein L7aRPL7A-1.0994.0165Transcription/RNA processing/translationP99999Cytochrome cCYCS-1.0634.0237Mitochondria/redoxP14927Cytochrome b-c1 complex subunit 7UQCRB-0.9939.0352Mitochondria/redoxO43181NADH dehydrogenase (ubiquinone) iron-sulfur protein 4; mitochondrialNDUFS4-0.9391.0220Mitochondria/redoxP4678340S ribosomal protein S10RPS10-0.8004.0412Transcription/RNA processing/translationQ9UNX360S ribosomal protein L26-like 1RPL26L1-0.795.0441Transcription/RNA processing/translationP6224140S ribosomal protein S8RPS8-0.7606.0362Transcription/RNA processing/translationQ0001355-kilodalton erythrocyte membrane proteinMPP1-0.6858.0323Immune responseQ9Y3U860S ribosomal protein L36RPL36-0.6824.0149Transcription/RNA processing/translationP04792Heat shock protein β-1HSPB1-0.6317.0415Protein folding/transportP20674Cytochrome c oxidase subunit 5A; mitochondrialCOX5A-0.6209.0430Mitochondria/redoxQ9BXW7Haloacid dehalogenase-like hydrolase domain-containing 5HDHD5-0.5832.0196Lipid metabolismP6208140S ribosomal protein S7RPS7-0.5799.0368Transcription/RNA processing/translationQ92520Protein FAM3CFAM3C-0.5691.0467Other (cytokine activity)Q86VU5Catechol O-methyltransferase domain-containing protein 1COMTD1-0.5488.0242Other (putative O-methyltransferase)Q15233Non-POU domain-containing octamer-binding proteinNONO-0.5382.0131Transcription/RNA processing/translationP0870840S ribosomal protein S17RPS17-0.5285.0429Transcription/RNA processing/translationQ5SSJ5Heterochromatin protein 1-binding protein 3HP1BP3-0.5232.0430Transcription/RNA processing/translationP26232Catenin α-2CTNNA2-0.5041.0231CytoskeletonO608256-phosphofructo-2-kinase/fructose-2;6-bisphosphatase 2PFKFB2-0.4706.0010Carbohydrate metabolismQ9BPW8Protein NipSnap homolog 1NIPSNAP1-0.4247.0273Mitochondria/redoxQ9BUJ2Heterogeneous nuclear ribonucleoprotein U-like protein 1HNRNPUL1-0.4204.0322Transcription/RNA processing/translationP51148Ras-related protein Rab-5CRAB5C-0.4166.0228Protein folding/transportA0AV96RNA-binding protein 47RBM47-0.4047.0211Other (RNA binding)P2637360S ribosomal protein L13RPL13-0.3879.0418Transcription/RNA processing/translationQ9Y6N9HarmoninUSH1C-0.3863.0445Other (brush-border assembly, regulation of microvillus length)Q5IFJ760S ribosomal protein L9RPL9-0.3797.0444Transcription/RNA processing/translationP36543V-type proton ATPase subunit E 1ATP6V1E1-0.3609.0298Mitochondria/redoxP1588040S ribosomal protein S2RPS2-0.313.0103Transcription/RNA processing/translationQ00169Phosphatidylinositol transfer protein α isoformPITPNA-0.2974.0315Lipid metabolismQ9Y4W6AFG3-like protein 2AFG3L2-0.2882.0427Protein metabolismQ9UBQ0Vacuolar protein sorting-associated protein 29VPS29-0.283.0334Protein folding/transportQ13232Nucleoside diphosphate kinase 3NME3-0.2655.0405Other (nucleotide triphosphate synthesis)P61106Ras-related protein Rab-14RAB14-0.2269.0176Protein folding/transportQ8NEV1Casein kinase II subunit α 3CSNK2A30.1846.0033Protein metabolismQ9BPX5Actin-related protein 2/3 complex subunit 5-like proteinARPC5L0.2192.0094Transcription/RNA processing/translationQ7L5N1COP9 signalosome complex subunit 6COPS60.2227.0237Protein metabolismO60313Dynamin-like 120-kilodalton protein; mitochondrialOPA10.2682.0189Mitochondria/redoxQ15029116-kilodalton U5 small nuclear ribonucleoprotein componentEFTUD20.2702.0022Transcription/RNA processing/translationQ92841Probable ATP-dependent RNA helicase DDX17DDX170.2774.0277Transcription/RNA processing/translationQ9Y265RuvB-like 1RUVBL10.2863.0143Transcription/RNA processing/translationQ08211ATP-dependent RNA helicase ADHX90.2969.0021Transcription/RNA processing/translationP56192Methionine-tRNA ligase; cytoplasmicMARS0.2985.0005Transcription/RNA processing/translationO00303Eukaryotic translation initiation factor 3 subunit FEIF3F0.3017.0358Transcription/RNA processing/translationP50990T-complex protein 1 subunit thetaCCT80.3103.0462Protein folding/transportQ13363C-terminal-binding protein 1CTBP10.3117.0193Transcription/RNA processing/translationO76094Signal recognition particle subunit SRP72SRP720.317.0088Transcription/RNA processing/translationP50851Lipopolysaccharide-responsive and beige-like anchor proteinLRBA0.3239.0462Immune responseQ13409Cytoplasmic dynein 1 intermediate chain 2DYNC1I20.3304.0080CytoskeletonQ6P2Q9Pre--messenger RNA-processing-splicing factor 8PRPF80.3428.0263Transcription/RNA processing/translationP46940Ras GTPase-activating-like protein IQGAP1IQGAP10.3464.0427Other (cellular response to calcium and growth factor stimuli)O95782AP-2 complex subunit α-1AP2A10.3545.0240Protein folding/transportP17987T-complex protein 1 subunit αTCP10.3631.0078Protein folding/transportQ14152Eukaryotic translation initiation factor 3 subunit AEIF3A0.3778.0231Transcription/RNA processing/translationO95394Phosphoacetylglucosamine mutasePGM30.3795.0164Carbohydrate metabolismO43143Pre--messenger RNA-splicing factor ATP-dependent RNA helicase DHX15DHX150.3864.0448Transcription/RNA processing/translationQ9P2J5Leucine-tRNA ligase; cytoplasmicLARS0.3966.0183Transcription/RNA processing/translationP13010X-ray repair cross-complementing protein 5XRCC50.4032.0284Transcription/RNA processing/translationO75643U5 small nuclear ribonucleoprotein 200-kilodalton helicaseSNRNP2000.404.0136Transcription/RNA processing/translationQ53EL6Programmed cell death protein 4PDCD40.4079.0175Transcription/RNA processing/translationQ8N163Cell cycle and apoptosis regulator protein 2CCAR20.4108.0094Transcription/RNA processing/translationQ1500826S proteasome non-ATPase regulatory subunit 6PSMD60.4158.0475Protein metabolismP00325Alcohol dehydrogenase 1BADH1B0.427.0394Mitochondria/redoxP07478Trypsin-2PRSS20.4359.0328Protein metabolismQ9Y262Eukaryotic translation initiation factor 3 subunit LEIF3L0.4529.0493Transcription/RNA processing/translationQ93009Ubiquitin carboxyl-terminal hydrolase 7USP70.455.0294Protein metabolismQ86VP6Cullin-associated NEDD8-dissociated protein 1CAND10.4561.0490Protein metabolismO00410Importin-5IPO50.4754.0232Protein folding/transportQ15393Splicing factor 3B subunit 3SF3B30.4946.0349Transcription/RNA processing/translationP07437Tubulin β chainTUBB0.5145.0031CytoskeletonP55011Solute carrier family 12 member 2SLC12A20.5237.0405Ion transportQ14974Importin subunit β-1KPNB10.5474.0326Protein folding/transportP0DOX7Immunoglobulin κ light chain0.5546.0356Immune responseP68363Tubulin α-1B chainTUBA1B0.5982.0022CytoskeletonP55786Puromycin-sensitive aminopeptidaseNPEPPS0.5983.0495Protein metabolismP11766Alcohol dehydrogenase class-3ADH50.5992.0360Mitochondria/redoxP05451Lithostathine-1-αREG1A0.6105.0107Other (positive regulator of cell proliferation, carbohydrate binding)Q9BUF5Tubulin β-6 chainTUBB60.6265.0332CytoskeletonP01619Immunoglobulin κ variable 3--20IGKV3-201.0274.0314Immune responseO00534von Willebrand factor A domain-containing protein 5AVWA5A1.1874.0346Other (may act as tumor suppressor)P08311Cathepsin GCTSG1.8843.0438Protein metabolismQ8IV08Phospholipase D3[b](#tbl7fnb){ref-type="table-fn"}PLD35.52491.31E-08Lipid metabolism[^14][^15][^16][^17]Table 8GO Terms Associated With Lipid Metabolism-Related Proteins Present in Duodenal Biopsy Specimens 10 Hours After a High-Fat Liquid MealCholesterol/steroid metabolism UP_KEYWORDSCholesterol biosynthesis GOTERM_BP_DIRECTCholesterol biosynthetic process UP_KEYWORDSCholesterol metabolism GOTERM_BP_DIRECTIsoprenoid biosynthetic process UP_KEYWORDSSteroid biosynthesis KEGG_PATHWAYSteroid hormone biosynthesis GOTERM_BP_DIRECTSteroid metabolic process UP_KEYWORDSSteroid metabolism UP_KEYWORDSSterol biosynthesis GOTERM_MF_DIRECTSterol esterase activity UP_KEYWORDSSterol metabolism CLD storage/metabolism GOTERM_CC_DIRECTLipid droplet GOTERM_BP_DIRECTLipid storageCM trafficking GOTERM_CC_DIRECTER to Golgi transport vesicle membraneEicosanoid metabolism GOTERM_MF_DIRECTArachidonic acid epoxygenase activity KEGG_PATHWAYArachidonic acid metabolism GOTERM_BP_DIRECTCyclooxygenase pathway GOTERM_BP_DIRECTEpoxygenase P450 pathway GOTERM_BP_DIRECTLeukotriene metabolic process UP_KEYWORDSProstaglandin biosynthesis GOTERM_BP_DIRECTProstaglandin biosynthetic process UP_KEYWORDSProstaglandin metabolism GOTERM_MF_DIRECTSteroid hydroxylase activityFA modification/metabolism/transport GOTERM_MF_DIRECTAcyl-CoA dehydrogenase activity INTERPROAcyl-CoA dehydrogenase, conserved site INTERPROAcyl-CoA dehydrogenase/oxidase INTERPROAcyl-CoA dehydrogenase/oxidase, C-terminal INTERPROAcyl-CoA dehydrogenase/oxidase, N-terminal GOTERM_MF_DIRECTAcyl-CoA hydrolase activity GOTERM_BP_DIRECTAcyl-CoA metabolic process INTERPROAcyl-CoA oxidase/dehydrogenase, central domain INTERPROAcyltransferase ChoActase/COT/CPT INTERPROAMP binding, conserved site INTERPROAMP-dependent synthetase/ligase UP_SEQ_FEATUREBinding site: carnitine GOTERM_MF_DIRECTDecanoate-CoA ligase activity INTERPRODomain of unknown function DUF4009 GOTERM_BP_DIRECTFatty acid α-oxidation GOTERM_BP_DIRECTFatty acid β-oxidation GOTERM_BP_DIRECTFatty acid β-oxidation using acyl-CoA dehydrogenase UP_KEYWORDSFatty acid biosynthesis KEGG_PATHWAYFatty acid biosynthesis KEGG_PATHWAYFatty acid degradation UP_KEYWORDSFatty acid metabolism KEGG_PATHWAYFatty acid metabolism GOTERM_MF_DIRECTFlavin adenine dinucleotide binding GOTERM_MF_DIRECTHydroxyacyl-CoA dehydrogenase activity GOTERM_BP_DIRECTLipid homeostasis GOTERM_BP_DIRECTLong-chain fatty acid import GOTERM_BP_DIRECTLong-chain fatty acid metabolic process GOTERM_MF_DIRECTLong-chain fatty acid--CoA ligase activity GOTERM_BP_DIRECTNegative regulation of fatty acid metabolic process GOTERM_MF_DIRECTOxidoreductase activity, acting on the CH-CH group of donors GOTERM_MF_DIRECTOxidoreductase activity, acting on the CH-CH group of donors, with a flavin as acceptor GOTERM_MF_DIRECTPalmitoyl-CoA hydrolase activity UP_SEQ_FEATURERegion of interest: coenzyme A binding GOTERM_MF_DIRECTTransferase activity, transferring acyl groups GOTERM_MF_DIRECTVery-long-chain fatty acid--CoA ligase activityLipid binding proteins INTERPROAcyl-CoA binding protein, ACBP INTERPROAcyl-CoA binding protein, ACBP, conserved site INTERPROCytosolic fatty acid binding UP_SEQ_FEATUREDomain: ACB GOTERM_MF_DIRECTFatty-acyl-CoA binding INTERPROLipocalin/cytosolic fatty acid binding protein domain GOTERM_MF_DIRECTRetinoic acid bindingLipoprotein metabolism INTERPROApolipoprotein A1/A4/E GOTERM_MF_DIRECTCholesterol binding GOTERM_BP_DIRECTCholesterol efflux GOTERM_BP_DIRECTCholesterol homeostasis GOTERM_BP_DIRECTCholesterol metabolic process GOTERM_MF_DIRECTCholesterol transporter activity GOTERM_CC_DIRECTChylomicron UP_KEYWORDSChylomicron GOTERM_BP_DIRECTChylomicron remnant clearance UP_KEYWORDSHigh-density lipoprotein GOTERM_CC_DIRECTHigh-density lipoprotein particle GOTERM_BP_DIRECTHigh-density lipoprotein particle assembly GOTERM_BP_DIRECTHigh-density lipoprotein particle clearance GOTERM_MF_DIRECTHigh-density lipoprotein particle receptor binding GOTERM_BP_DIRECTHigh-density lipoprotein particle remodeling GOTERM_CC_DIRECTIntermediate-density lipoprotein particle GOTERM_MF_DIRECTLipase inhibitor activity UP_KEYWORDSLipid transport GOTERM_BP_DIRECTLipid transport GOTERM_MF_DIRECTLipid transporter activity GOTERM_BP_DIRECTLipoprotein biosynthetic process GOTERM_BP_DIRECTLipoprotein metabolic process GOTERM_CC_DIRECTLow-density lipoprotein particle GOTERM_BP_DIRECTLow-density lipoprotein particle remodeling GOTERM_BP_DIRECTNegative regulation of cholesterol transport GOTERM_BP_DIRECTNegative regulation of lipid catabolic process GOTERM_BP_DIRECTNegative regulation of lipid metabolic process GOTERM_BP_DIRECTNegative regulation of receptor-mediated endocytosis GOTERM_BP_DIRECTNegative regulation of VLDL particle clearance GOTERM_BP_DIRECTNegative regulation of VLDL particle remodeling GOTERM_MF_DIRECTPhosphatidylcholine binding GOTERM_MF_DIRECTPhosphatidylcholine-sterol O-acyltransferase activator activity GOTERM_BP_DIRECTPhospholipid efflux GOTERM_BP_DIRECTPositive regulation of cholesterol esterification GOTERM_BP_DIRECTPositive regulation of fatty acid biosynthetic process GOTERM_BP_DIRECTPositive regulation of lipoprotein lipase activity GOTERM_BP_DIRECTPositive regulation of triglyceride catabolic process GOTERM_BP_DIRECTRegulation of Cdc42 protein signal transduction GOTERM_BP_DIRECTRegulation of intestinal cholesterol absorption GOTERM_BP_DIRECTReverse cholesterol transport GOTERM_CC_DIRECTSpherical high-density lipoprotein particle GOTERM_BP_DIRECTTriglyceride catabolic process GOTERM_BP_DIRECTTriglyceride homeostasis GOTERM_CC_DIRECTVLDL particle GOTERM_BP_DIRECTVLDL particle remodeling UP_KEYWORDSVLDLTAG and PL synthesis/metabolism GOTERM_MF_DIRECT1-Acylglycerol-3-phosphate O-acyltransferase activity GOTERM_MF_DIRECT1-Acylglycerol-3-phosphate O-acyltransferase activity GOTERM_BP_DIRECTAcylglycerol catabolic process GOTERM_BP_DIRECTCDP-diacylglycerol biosynthetic process GOTERM_BP_DIRECTCDP-diacylglycerol biosynthetic process GOTERM_BP_DIRECTGlycerophospholipid biosynthetic processGlycerophospholipid biosynthetic process GOTERM_BP_DIRECTGlycerophospholipid catabolic process KEGG_PATHWAYGlycerophospholipid metabolism GOTERM_BP_DIRECTPhosphatidic acid biosynthetic process UP_KEYWORDSPhospholipid biosynthesis GOTERM_BP_DIRECTPhospholipid biosynthetic process UP_KEYWORDSPhospholipid metabolism INTERPROPhospholipid/glycerol acyltransferase GOTERM_BP_DIRECTTriglyceride biosynthetic process GOTERM_BP_DIRECTTriglyceride lipase activity[^18]Table 9Lipid Metabolism Proteins Present at Relatively Different Levels in Duodenal Biopsy Specimens in Response to Glucose or Water Consumption After an Overnight Fast After the Consumption of a High-Fat Liquid MealUniprot accessionProtein nameGene nameFold change*t* test *P* valueLipid metabolism-related functionP33897ATP binding cassette subfamily D member 1[a](#tbl9fna){ref-type="table-fn"}ABCD1-5.296.00108FA modification/ metabolism/transportQ9BXW7Haloacid dehalogenase-like hydrolase domain-containing 5HDHD5-0.5832.0196TAG and PL synthesis/metabolismQ00169Phosphatidylinositol transfer protein α isoformPITPNA-0.2974.0315Lipoprotein metabolismP00325Alcohol dehydrogenase 1BADH1B0.427.0394FA modification/ metabolism/transportP11766Alcohol dehydrogenase class-3ADH50.5992.0360FA modification/ metabolism/transportQ8IV08Phospholipase D3[b](#tbl9fnb){ref-type="table-fn"}PLD35.52491.31E-08TAG and PL synthesis/ metabolism[^19][^20][^21][^22]

Discussion {#sec2}
==========

In the current study we investigated the effect of oral glucose ingestion on lipid stored in the intestine from a previous meal. We not only confirmed the ability of oral glucose to mobilize intestinal lipid stores and increase plasma CM TGs, but also expanded this observation with high-quality visualization of subcellular CLDs and lipids within the secretory pathway, as well as an examination of the intestinal proteome, to explore cellular mechanisms. Through detailed quantitative analysis of subcellular lipid depots, we showed that glucose ingestion reduced both the number and size of CLDs within enterocytes. Furthermore, our proteomic analysis of duodenal biopsy specimens showed marked differential presence of intestinal proteins in response to oral glucose compared with water, some of which may be involved in regulating the mobilization of intestinal lipid stores.

The results of the current study provide further evidence that lipid can be retained within the small intestine for many hours after fat ingestion and subsequently mobilized by a stimulus, as reviewed in the introduction. Although visualization of lipid depots in jejunal biopsy specimens was reported in a previous study,[@bib9] our study added to the literature with examination of duodenal biopsy specimens and provided visualization of the subcellular localization of lipid droplets in the cell and in the secretory pathway. We detected the presence of abundant lipid depots, especially CLDs, within the duodenal enterocytes of subjects who ingested a high-fat meal 6 hours before the biopsy and water 1 hour before the intestinal biopsy (ie, the control study). This lipid retention in duodenal enterocytes was seen at a time that plasma TGs had almost returned to baseline, clearly showing that lipids are being retained in the intestine. Glucose ingestion acutely (within 1 hour) reduced the total amount of lipid retained in enterocytes, providing evidence of glucose-stimulated lipid mobilization. This corresponded to a spike in total plasma TGs, which was mainly owing to an increase in CM TGs. Because there was no other food intake during the study period, the high-fat liquid meal likely was the source of this TG spike. Together, these results suggest that considerable dietary lipid is retained in intestinal CLDs well into the late postprandial period, which subsequently can be mobilized and secreted within CMs. Although the results of the current study show an intracellular mechanism of CLD mobilization, lymph flow and mobilization of extracellular (eg, in lamina propria) CMs also could contribute to the overall mobilization of intestinal lipid stores. Glucose in the luminal fluid increases sympathetic activity, leading to vasodilation of the submucosal arterioles, and enhances intestinal blood flow in rodent models. Changes in vasodilation and blood flow and the potential in mediating the total response of lipid mobilization to glucose ingestion were not assessed in the current study. Increased insulin secretion after glucose ingestion also may lead to vasodilation in muscle. This may help mobilize total TG stores, but the effects of insulin on CLD mobilization are unknown. These aspects warrant further study using animal models.

This study identifies CLDs as dynamic and regulated lipid storage depots that mediate intestinal lipid handling and CM secretion. The ability to store TGs in CLDs and mobilize this lipid pool at later times likely contributes to the efficiency of dietary fat absorption and helps prevent toxicity both locally within enterocytes as well as systemically.[@bib4], [@bib16], [@bib17] In the enterocyte, CLDs provide a buffering depot for lipids that cannot be rapidly incorporated into CMs for secretion. Systemically, this process also may attenuate an otherwise rapid increase in postprandial lipids that could overwhelm the lipid storage and buffering capacity of adipose tissues, resulting in fatty acid spillover and lipotoxicity.[@bib21] Furthermore, early postprandial CLD mobilization may serve as a priming function for the enterocyte's CM assembly and secretion pathway, which needs to rapidly and efficiently cope with the large influx of ingested dietary lipids during food ingestion. Quantifying lipid depots in subcellular compartments and organelles, such as detailed assessment of size distribution of chylomicrons within Golgi, may yield important information on the underlying mechanism, which was not possible with EM visualization. Together with the increase in plasma and CM TG concentrations, the results of the current study support that oral glucose functioned as a stimulus to mobilize enterocyte lipid stores for use in CM synthesis and secretion. Based on the known and well-described biology of CM assembly and secretion,[@bib2] it is hypothesized that glucose ingestion would have initiated a sequence of events, including hydrolysis of CLD TGs, TG resynthesis in the ER membrane, CM assembly and secretion from the enterocytes, and CM transport through the lymphatics into circulation. It remains to be determined if other stimuli for intestinal lipid mobilization (eg, sham fat feeding[@bib8] and GLP-2[@bib19]) mobilize intestinal lipids by a similar mechanism, and whether their effects are quantitatively similar to that of oral glucose. Although glucose ingestion may stimulate the secretion of GLP-2, which mobilizes CM release, the observed effects of glucose ingestion on CLDs was unlikely owing to GLP-2 secretion. GLP-2 concentrations after 25-gram glucose ingestion is unknown and was not measured in this study because of a lack of blood samples with dipeptidyl peptidase-4 inhibitor. In healthy subjects, a standard oral glucose tolerance test (75 g D-glucose) increased plasma glucose concentrations from approximately 5 to approximately 9 mmol/L, and plasma GLP-2 concentrations from approximately 15 to 49 pmol/L.[@bib22] Mixed meal ingestion increased plasma GLP-2 (intact, 16 ± 3 to 73 ± 10 pmol/L at 90 min), and subcutaneous injection of 400 ug GLP-2 increased intact GLP-2 to maximally 1493 ± 250 pmol/L at 45 minutes in healthy volunteers.[@bib23] In our previous study in which GLP-2 promoted release of preformed chylomicrons, a more than 3-fold higher dose of GLP-2 was used (1500 ug),[@bib19] which is expected to increase circulating GLP-2 even more significantly. In addition, because GLP-1 and GLP-2 are co-secreted, glucose ingestion--stimulated secretion of GLP-2 is accompanied by secretion of GLP-1, which is known to suppress CM secretion.[@bib24] Interestingly, we found that the effects of glucose ingestion are dependent on sufficient lipid stores within the enterocyte. After prolonged fasting (10 hours after fat ingestion), which resulted in a significant reduction in intestinal CLD stores, glucose had no effect on intestinal lipid stores.

To gain further insight into proteins potentially regulating the observed glucose-stimulated lipid mobilization within the small intestine, we performed a comparative proteomic analysis of the duodenal biopsy specimens in response to glucose compared with water ingestion. Previous studies have used both untargeted and targeted approaches to identify duodenal proteins in insulin-resistant compared with insulin-sensitive individuals, but these duodenal tissue samples were collected in the fasted state.[@bib25], [@bib26] Although validation of the presence of the identified proteins within the small intestine by additional methods is needed, the present study provides us with candidate proteins that are present in the duodenum in response to dietary fat and glucose ingestion. This study also identified potential glucose-regulated proteins within the duodenum, some of which also may be involved in regulating glucose-stimulated mobilization of lipids from the small intestine. In the current study we initially used a *P* value less than .05 as the cut-off value to identify proteins differentially present between treatment groups. After Bonferroni correction for multiple comparisons, a few proteins were still present at significantly different levels between the groups. It is important to note that the Bonferroni correction is a stringent correction factor that minimizes false-positive results, but it also increases false-negative results. Therefore, although this correction factor helps prioritize candidate proteins for further investigation, the current proteomic analysis is a hypothesis-generating experiment, and it is therefore also important to not completely disregard the proteins that were no longer present at significantly different levels after this correction.

To identify proteins potentially involved in regulating glucose-stimulated lipid mobilization from the small intestine, we performed a targeted search of our proteomics data to identify proteins with known roles in intestinal lipid/lipoprotein metabolism and transport. The results suggest differential regulation of proteins involved in fatty acid metabolism, cholesterol synthesis, and lipid binding. Little is known about the particular roles of these proteins within the small intestine specifically. However, acyl-coenzyme A binding protein previously was shown to be present at high levels in mouse intestinal epithelium and to co-localize with fatty acid binding protein 2 (intestinal fatty-acid binding protein).[@bib27] Fatty acid binding protein 2 also was identified in the current study but was present at similar levels in both treatments. Interestingly, we found that ethanolaminephosphotransferase 1 was relatively up-regulated by glucose ingestion. This protein is involved in the synthesis of phosphatidylethanolamine.[@bib28] Mutations in several enzymes involved in phospholipid synthesis are associated with diseases including fatty liver, lipodystrophy, and obesity.[@bib29] In addition, altering the phospholipid composition of CLDs, CMs, and the ER all have the potential to impact lipid storage and secretion, such as in phospholipid remodeling protein lysophosphatidylcholine acyltransferase-3 deficiency.[@bib30] Therefore, it is possible that higher levels of ethanolaminephosphotransferase 1 in the intestine in response to glucose has an impact on membrane composition of the ER and/or CMs that ultimately promotes CM secretion. Validation of the presence and localization of these proteins within the small intestine, which was not possible owing to a lack of suitable samples in this study, is required in future studies, but their initial identification and differential presence in the 2 treatment groups suggests there may be a general increase in intestinal lipid metabolism in response to glucose consumption. Furthermore, the differentially present lipid metabolism-related proteins identified in biopsy specimens after prolonged (10 hours) fasting were not the same as those identified in the shorter (6 hour) fasting study, but they were involved in similar processes. This suggests that glucose may exert different regulatory effects depending on dietary status (ie, when the last meal was consumed).

Interestingly, we did not see differences in the levels of several proteins with established roles in CM synthesis and secretion or CLD metabolism between treatments. We identified both perilipin 2 and perilipin 3, which play roles in regulating CLD storage,[@bib31] but these proteins were present at similar levels in both treatment groups. In addition, we only identified 1 of the 4 enzymes involved in cytoplasmic TG lipolysis, monoacylglycerol lipase, in the current study, and it was not differentially present in response to glucose compared with water ingestion. This is consistent, however, with the lack of identification of any cytoplasmic lipases other than monoacylglycerol lipase within duodenal tissues collected from fasted insulin-sensitive or insulin-resistant individuals.[@bib26] It is possible that these proteins are present at levels below the mass spectrometry detection limit, and/or that other enzymes or pathways play more of a role in TG mobilization from enterocytes under the conditions of the current study. In fact, we identified lysosomal acid lipase, which hydrolyzes TGs within the lysosome during lipophagy,[@bib32] at similar levels in both treatment groups, along with several other lipases. We also identified key proteins involved in CM synthesis and trafficking (apolipoprotein B, microsomal triglyceride transfer protein, secretion associated ras related GTPase 1B), but again did not see differences in their protein levels in response to glucose compared with water ingestion. However, it still is possible that glucose ingestion alters the activities (eg, through phosphorylation) or subcellular localization of proteins involved in CM synthesis and CLD metabolism, which requires further investigation in future studies.

To examine whether proteins without known roles in lipid metabolism are involved in the observed glucose-stimulated mobilization from the small intestine, we also examined non--lipid-related proteins. This analysis showed that glucose down-regulated syntaxin-binding protein 5. This protein has been shown to be a negative regulator of soluble *N*-ethylmaleimide-sensitive factor attachment protein receptor (SNARE) protein assembly required for insulin exocytosis in β cells. In addition, glucose has been shown to inhibit syntaxin-binding protein 5 and induce its degradation in these cells to promote insulin secretion.[@bib33] Furthermore, it regulates vesicle exocytosis in other cell types, including platelets and endothelial cells.[@bib34] In enterocytes, SNARE complex is required for prechylomicron transport vesicle intracellular transport during chylomicron synthesis and secretion. After budding from the ER, prechylomicron transport vesicles are directed by vesicle SNARE toward the Golgi. Vesicle associated membrane protein 7 of the vesicle SNARE joins with syntaxin-5, rbet1, and vti1a of the target SNARE to form the SNARE complex, which facilitates docking and fusion of prechylomicron transport vesicle with the Golgi membrane.[@bib35] The roles of syntaxin-binding protein 5 in enterocytes are not elucidated, but our data suggest that glucose negatively regulates this protein in enterocytes, and that this regulation may have an impact on intestinal lipid mobilization. Another protein that draws attention is epimerase family protein SDR39U1, which was up-regulated by glucose. This protein is expressed in small intestine, including the duodenum.[@bib36] It belongs to a family of enzymes involved in the metabolism of a large variety of compounds, including steroid hormones, prostaglandins, retinoids, lipids, and xenobiotics.[@bib37] Genetic defects in SDR genes underlie several inherited metabolic diseases.[@bib38] Further investigation into the intestine-specific functions of these proteins would be beneficial because of their possible involvement in glucose-stimulated lipid mobilization from the intestine.

Conclusions {#sec3}
===========

Here, we present evidence from both in vivo lipid responses and intestinal biopsy specimens that support a role of glucose ingestion in mobilizing lipid stores from the human intestine. Glucose ingestion mobilizes enterocyte CLDs to provide substrate for CM synthesis and secretion, likely involving multiple molecular players. Although the precise mechanisms by which intestinal lipid stores are mobilized remain unknown, the current study has highlighted candidate proteins and pathways that may regulate this process and can inform future studies investigating the regulation of this process. An increased understanding of the regulation of intestinal lipid storage and mobilization may help provide novel dietary guidance for lowering blood TG levels and identify novel therapeutic targets for treatment of hypertriglyceridemia to reduce cardiovascular disease risk.

Materials and Methods {#sec4}
=====================

Aim 1 {#sec4.1}
-----

### Subjects {#sec4.1.1}

Six healthy men were recruited through advertisement in a local newspaper. Subjects were in good health, with no known medical conditions, and were not taking any medication. The study protocol was approved by the Research Ethics Board at the University Health Network, University of Toronto. All participants provided written informed consent.

### Study protocol {#sec4.1.2}

Each subject was studied on 2 occasions, 4--6 weeks apart, in random order. On each occasion, subjects were admitted to the Metabolic Test Centre at the Toronto General Hospital after an overnight fast. An indwelling catheter was inserted into a superficial arm vein for blood sampling. At 7 AM (referred to as t = 0), subjects ingested a 100-mL high-fat liquid meal (Calogen; Nutricia Advanced Medical Nutrition, Wiltshire, UK). Each 100 mL of the liquid meal contains 450 kcal energy, 50 g fat (5.3 g saturated fat, 30.4 g monounsaturated fat, 14.3 g polyunsaturated fat), 0 g protein, and 0.1 g carbohydrate. Five hours later (t = 5 h), subjects ingested a glucose solution (50%, 50 mL) in 1 arm of the study and 50 mL water in the other arm, 4--6 weeks apart. Blood samples were drawn at baseline and at regular intervals until the end of the study (t = 8 h).

### Laboratory analysis {#sec4.1.3}

TRL was first isolated as previously described.[@bib24] CM and VLDL-sized particles were isolated further from TRL, according to a previously described method with modifications.[@bib19], [@bib39] TRL fractions (1 mL) were transferred to a 6-mL centrifuge tube on ice, carefully overlaid with 1.006 g/mL density NaBr solution, and centrifuged at 13,500 rpm for 30 minutes at 12°C using a Ti50.4 rotor. Clear separation was visible between the top and bottom fractions. The top 0.5 mL was collected as CM by tube slicing, whereas the bottom fraction was collected as VLDL-sized lipoproteins. Plasma glucose was measured at the bedside with a glucose analyzer (Analox Instruments, Stourbridge, UK). TG in plasma and lipoprotein fractions were measured with a commercial kit (Roche Diagnostics, Indianapolis, IN). Plasma insulin was measured with a human insulin radioimmunoassay kit (Millipore, Burlington, MA).

Aim 2 {#sec4.2}
-----

### Subjects {#sec4.2.1}

Twenty-four individuals undergoing diagnostic gastroduodenoscopy for gastrointestinal symptoms were recruited after obtaining informed consent. Subjects were referred for endoscopy after complaints of heartburn, dyspepsia, bloating, abdominal pain, nausea without vomiting, reflux, gas, and regurgitation. Participants had no known duodenal pathology and were observed to have normal duodenal mucosa by visual inspection during the endoscopy. The study protocol was approved by the Human Research Ethics Board of the University Health Network, University of Toronto. All participants provided written informed consent.

### Study protocol {#sec4.2.2}

After providing informed consent, participants were block-randomized to receive either oral glucose or water treatment. At 7 AM after an overnight fast (referred to as t = 0), subjects ingested a 100-mL high-fat liquid meal containing 50 g of fat (Calogen; Nutricia Advanced Medical Nutrition). Five hours later (t = 5 h), subjects ingested either a glucose solution (50%, 50 mL) or 50 mL water. One hour after ingesting either glucose or water (t = 6 h), duodenal biopsy samples were obtained during an endoscopy. Although quantitatively jejunum is responsible for the majority of lipid absorption, active absorption also occurs in duodenum[@bib40] and obtaining biopsy specimens from the duodenum as compared with jejunum is more technically feasible and was acceptable to our human ethics review committee. Samples were snap-frozen in dry ice and stored at -80°C for later proteomic analysis or preserved in 2.5% glutaraldehyde in 0.1 mol/L sodium cacodylate (pH 7.4) and stored at 4°C for electron microscopy.

### Delayed fasting {#sec4.2.3}

To further examine the time course of fat retention in the intestine and its subsequent mobilization by oral glucose, duodenal biopsy specimens were taken from an additional 10 individuals. These individuals were randomly assigned to ingest glucose or water 9 hours after ingestion of the high-fat liquid meal, which was administered at 10 PM the night before undergoing the gastroduodenoscopy. The study protocol was otherwise identical to that described earlier for aim 2.

### Transmission electron microscopy {#sec4.2.4}

Duodenal biopsy samples were immediately fixed using 2.5% glutaraldehyde in 0.1 mol/L sodium cacodylate (pH 7.4) and stored at 4°C until processed. The tissues then were fixed with a secondary fixative, 1% osmium tetroxide in 0.1 mol/L sodium cacodylate (pH 7.4) for 1 hour at room temperature, washed repeatedly in distilled deionized water, dehydrated with a graded series of ethanol, and embedded in Embed 812 resin (Electron Microscopy Sciences, Hatfield, PA). Thick sections (0.5 μm) were stained with 1% toluidine blue and examined by light microscopy to confirm tissue orientation. Thin sections (80 nm) were cut on a Leica (Leica Microsystems Inc, Buffalo Grove, IL) UC6 ultramicrotome and stained with 2% uranyl acetate and lead citrate. Images were either acquired on a Tecnai T20 transmission electron microscope (FEI, Hillsboro, OR) equipped with an LaB6 source and operating at 100 kV, or a CM-100 transmission electron microscope (FEI/Philips, Hillsboro, OR) operating at 80 kV. Intact enterocytes were examined for the presence of CLDs (40--63 enterocytes/sample, 5 or 12 samples/group). Quantitative analyses were performed on enterocytes containing CLDs. The number of CLDs per enterocyte was counted and the diameters of individual CLDs were measured using ImageJ software (NIH, Bethesda, MD). Measured diameters were used to estimate the area of individual CLDs (area = π (diameter/2)^2^), and the total CLD area per enterocyte was estimated by multiplying the average CLD area by the average CLD number. Qualitative assessments of lipids within the secretory pathway (ER, Golgi, and secretory vesicles) were made with a ranking system. Because it was too difficult to determine quantitatively the area of lipids within the secretory pathway, an in-house ranking system was used to arbitrarily classify each enterocyte as containing high, moderate, or low lipid content. Individual enterocytes were classified as containing low, moderate, or high amounts of secretory lipid, and then this information was used to assign each biopsy sample an overall ranking of low, moderate, or high. Previous electron microscopic analyses of intestinal lipid stores were used as a reference for the identification of intestinal lipid storage pools in the current study.[@bib41], [@bib42], [@bib43], [@bib44], [@bib45]

### Sample preparation for liquid chromatography--mass spectrometry/mass spectrometry analysis {#sec4.2.5}

Biopsy samples were washed once with 100 μL purified water followed by 100 μL washes using 100 mmol/L ammonium bicarbonate until the supernatant was clear, to remove the presence of blood in some samples. Tissue samples then were placed into 2-mL reinforced tubes containing 2.8-mm ceramic (zirconium oxide) beads (Cayman Chemical, Ann Arbor, MI). A total of 200 μL of 100 mmol/L ammonium bicarbonate was added to each sample, and the tubes were loaded into a Precellys 24 homogenizer (Berlin Instruments, Rockville, MD). The tissue was homogenized at 6500 rpm using 3 cycles of 20 seconds each. Protein concentrations were determined for each of the tissue solutions using a Pierce BCA assay kit (Thermo Scientific, Waltham, MA). An aliquot containing 100 μg protein was taken for processing. Before the digestion, the protein was precipitated and concentrated from solution using acetone. After drying the precipitated pellets, the protein samples were reduced using 10 mmol/L 1,4-dithiothreitol followed by alkylation using iodoethanol. Sequence grade Lys-C/Trypsin (Promega, Madison, WI) was used to enzymatically digest the protein samples in the Barocycler NEP2320 (Pressure Biosciences, Inc, Easton, MA) at 50°C under 20,000 psi for 1 hour. Digested samples were cleaned using C18 spin columns (Nest Group, Southborough, MA) and dried. Resulting pellets were resuspended in 97% purified water/3% acetonitrile/0.1% formic acid before liquid chromatography/mass spectrometry analysis.

### Liquid chromatography--mass spectrometry/mass spectrometry {#sec4.2.6}

Digested samples were analyzed using the Dionex UltiMate 3000 RSLC Nano System coupled to a Q Exactive HF Hybrid Quadrupole-Orbitrap Mass Spectrometer (Thermo Fisher Scientific). Peptides generated during the digestion were loaded onto a 300 μm inner diameter × 5 mm C18 PepMap 100 (Thermo Fisher Scientific) trap column and washed with 98% purified water/2% acetonitrile/0.01% formic acid using a flow rate of 5 μL/min. The trap column was switched in-line with the analytical column after 5 minutes, and peptides were separated over a 75 μm × 150 mm reverse-phase Acclaim PepMap RSLC C18 analytical column using a 120-minute method at a flow rate of 300 nL/min. Mobile phase A contained 0.01% formic acid in water and mobile phase B consisted of 0.01% formic acid in 80% acetonitrile. The linear gradient began at 5% B and reached 30% B in 80 minutes, 45% B in 91 minutes, and 100% B in 93 minutes. The column was held at 100% B for the next 5 minutes before returning to 5% B, where it was equilibrated for 20 minutes. Samples were injected into the QE HF through the Nanospray Flex Ion Source fitted with a stainless-steel emission tip (Thermo Scientific). Data acquisition was performed by monitoring the top 20 precursors at 120,000 resolution with an injection time of 100 ms.

### Proteomic data analysis {#sec4.2.7}

The results from the mass spectrometer were processed using the MaxQuant (Max-Planck Institute for Biochemistry, Martinsried, Germany) computational proteomics platform.[@bib46] The peak list generated was searched against the Homo sapiens sequences from UniProt and a common contaminants database. The following settings were used for the MaxQuant run: trypsin and Lys-C digestion enzymes with 2 missed cleavages allowed, ethanolyl addition to cysteine as a fixed modification, N-terminal acetylation and oxidation of methionine as variable modifications, with 3 modifications allowed for each peptide, default Orbitrap parameters, minimum peptide length of 7 amino acids, label-free quantification was selected, match between runs was selected and the interval was set to 1 minute, and the protein false-discovery rate was set to 1%. An in-house script was used to perform the following on the MaxQuant results: remove all of the contaminant proteins, log transform (log~2~\[x\]) the label-free quantification intensity values, and input missing values using half of the highest intensity when all the values for a given protein were missing in 1 group and present in at least 3 samples of the other group. Only proteins that were identified in at least 3 samples in 1 treatment group were considered present in the duodenal biopsy samples. Only the relative label-free quantification values of proteins that were identified in at least 3 samples in both treatment groups, or identified in at least 3 samples in 1 treatment group and 0 samples in the other treatment group (imputed values used) were compared statistically. The statistical analyses were performed in the R environment ([www.cran.r-project.org](http://www.cran.r-project.org){#intref0010}). A *t* test was performed on the label-free quantification intensities, with a *P* value \< .05 considered a statistically significant difference between the groups. The differentially present proteins were classified into broad groups based on GO terms for biological process or molecular function using the Database for Annotation, Visualization, and Integrated Discovery version 6.7 and the UniProt database. Proteins with GO terms related to lipid (TG, phospholipid, cholesterol, and fatty acid) metabolism, lipoprotein metabolism and transport, and CLD storage and metabolism were identified and classified using the Database for Annotation, Visualization, and Integrated Discovery functional annotation clustering and functional annotation tables as well as the UniProt database. Protein--protein interactions were visualized with Search Tool for the Retrieval of Interacting Genes/Proteins version 10.5 using the confidence view (high confidence, score 0.700).

### Statistical analysis {#sec4.2.8}

Data are presented as means ± SE. Plasma glucose concentrations, plasma TG concentration vs time curves, and lipoprotein fractions (TRL, CM, and VLDL) were compared using repeated-measures analysis of variance with post hoc analysis using a paired *t* test. Mean CLD numbers, diameters, and areas were compared using a *t* test. CLD diameter distribution was compared with the Kolmogorov--Smirnov test. Secretory lipids were assessed using a Fisher exact test.
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[^1]: BMI, body mass index.

[^2]: NOTE. Data are means ± SE for BMI and age.

[^3]: BMI, body mass index; F, female; M, male.

[^4]: NOTE. Data are means ± SE for BMI and age.

[^5]: BMI, body mass index; F, female; M, male.

[^6]: NOTE. Proteins identified in at least 3 samples in both groups, or at least 3 samples in 1 group and 0 samples in the other group, were compared. Proteins present at significantly different levels within the 2 treatment groups (*P* \< .05, *t* test) are shown. Average fold change of proteins in response to glucose relative to water consumption are presented. Numbers in the "Fold change" column represent how much higher (or lower if negative) the protein levels were in the glucose group compared with the water group. Proteins are listed in descending order according to relative fold change, with negative fold change values indicating relative down-regulation by glucose (listed at the top of the table) followed by those up-regulated by glucose indicated by a positive fold change (with greatest positive fold change listed at the bottom of table).

[^7]: ADP, adenosine diphosphate; ATP, adenosine triphosphate; ATPase, adenosine triphosphatase; cAMP, cyclic adenosine monophosphate; ERAD, endoplasmic-reticulum-associated protein degradation; NADP, nicotinamide adenine dinucleotide phosphate; redox, reduction-oxidation; tRNA, transfer ribonucleic acid.

[^8]: Only identified in response to water.

[^9]: Only identified in response to glucose.

[^10]: ABCP, Acyl-CoA-binding protein; ACB, acyl-CoA-binding; AMP, Adenosine monophosphate; CDP, Cytidine Diphosphate; COPII, cytoplasmic coat protein complex II; GPI, glycosylphosphatidylinositol; HDL, high-density lipoprotein; LDL, low-density lipoprotein; LDLa, low-density lipoprotein receptor domain class A; NAD, Nicotinamide adenine dinucleotide.

[^11]: NOTE. Proteins known to play a role in lipid metabolism were identified based on GO terms. Relative levels of proteins identified in at least 3 duodenal biopsy samples per group, or identified in at least 3 samples in 1 group and 0 samples in the other group, were compared. Proteins present at significantly different levels within the 2 treatment groups (*P* \< .05, *t* test) are shown. Average fold changes of proteins in response to glucose relative to water consumption are presented. Numbers in the "Fold change" column represent how much higher (or lower if negative) the protein levels were in the glucose group compared with the water group. All of these lipid metabolism proteins were up-regulated by glucose relative to water consumption and are listed in ascending order of magnitude of fold change.

[^12]: PL, phospholipid; TAG, triacylglycerol.

[^13]: Only identified in response to glucose.

[^14]: NOTE. Duodenal biopsy samples were collected 10 hours after lipid and 1 hour after glucose or water ingestion from patients undergoing a diagnostic endoscopy (n = 5 patients per group). Proteins that were identified in at least 3 samples in both groups and present at relatively different levels (*P* \< .05, *t* test), or at least 3 samples in 1 group and 0 samples in the other group, are shown. Average fold changes of proteins in response to glucose relative to water consumption are presented. Numbers in the "Fold change" column represent how much higher (or lower if negative) the protein levels were in the glucose group compared with the water group.

[^15]: AMBP, alpha-1-microglobulin/bikunin precursor; AP-2, adaptor protein complex 2; ATP, adenosine triphosphate; ATPase, adenosine triphosphatase; GTPase, guanosine triphosphatase; rBAT, neutral and basic amino acid transport protein; redox, reduction-oxidation; tRNA, transfer ribonucleic acid.

[^16]: Only identified in response to water.

[^17]: Only identified in response to glucose.

[^18]: ACBP, acyl-CoA-binding protein; AMP, adenosine monophosphate; CDP, cytidine diphosphate; COT/CPT, carnitine octanoyltransferase/carnitine palmitoyltransferase.

[^19]: NOTE. Duodenal biopsy samples were collected 10 hours after lipid and 1 hour after glucose or water ingestion from patients undergoing a diagnostic endoscopy (n = 5 patients per group). Lipid metabolism-related proteins were identified based on GO terms, and relative levels of proteins identified in at least 3 duodenal biopsy samples per group, or identified in at least 3 samples in 1 group and 0 samples in the other group, were compared. Numbers in the "Fold change" column represent how much higher (or lower if negative) the protein levels were in the glucose group compared with the water group. Proteins present at significantly different levels within the 2 treatment groups (*P* \< .05, *t* test) are shown.

[^20]: ATP, adenosine triphosphate; PL, phospholipid, TAG, triacylglycerol.

[^21]: Only identified in response to water.

[^22]: Only identified in response to glucose.
